Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04596397
Other study ID # 2020/104044
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 16, 2020
Est. completion date March 25, 2021

Study information

Verified date April 2021
Source Sorlandet Hospital HF
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An increasing proportion of pregnant women have their labors induced due to changing guidelines. In correlation with this increase, the population of the induced women has changed toward more women with a low-risk pregnancy. Traditionally, induction of labor has taken place in an inpatient setting where the women have spent extra days in hospital before delivery. Oral prostaglandins, such as misoprostol, is one of the most commonly used induction agent and is easy for the pregnant women to administrate. The pharmacological effect is ripening the cervix and compared to the mechanical cervical ripening, with a balloon catheter, the demands on busy maternity services seems reduced. Before contractions start, the risk of adverse effects on mother or fetus is considered low, but the evidence on use of misoprostol in an outpatient setting is sparse.


Description:

The implementation of induction of labor in outpatient settings is increasing despite insufficient evidence regarding safety and effectiveness. The use of a balloon catheter in an outpatient setting is not associated with adverse outcomes in a low-risk population. There is also evidence that outpatient vs inpatient induction of labor with balloon catheter is equally effective. Examination of vaginal dinoprostone (prostaglandin E2) is found to be efficacious in outpatient settings. However, strong evidence concludes that the oral route of administration of prostaglandin is preferable when inducing labor. The World Health Organization recommend 25ug misoprostol (prostaglandin E1) orally every 2 hour until contractions start for induction of labor. The women randomized to an inpatient setting will receive the hospital standard follow-up; oral misoprostol 25ug every two hours and a cardiotocography for fetal monitoring every 4-6 hour until start of contractions for two days. The women randomized to an outpatient setting will receive one oral misoprostol 25ug at the maternity unit. After two hours, provided a normal cardiotocography and no contractions, they can go home. They will continue to take 25ug misoprostol every two hours until start of contractions or increasing pain. Maximum time spent at home will be 48 hours. A dedicated midwife on call will always be available for questions. The women will receive oral and written information to return to the maternity unit if the water breaks, if they experience increasing pain or bleeding, if they feel insecure or anxious, if there are reduced or no fetal movements, and/or when the contraction starts. When the woman returns, she will stay admitted until delivery. All women will be given standard of care and fetal surveillance when admitted to the hospital, when the contractions start or if the contractions are still absent after 48 hours. We will also ask eligible women who refrain to participate about their reasons for non-participation. PRIMARY RESEARCH QUESTION We aim to explore that induction of labor using oral misoprostol appears feasible in an outpatient setting and may positively influence the length of the hospital stay and maternal satisfaction. PRIMARY RESEARCH PLAN This is a pilot study to explore the feasibility of a possible multicenter randomized controlled trail.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date March 25, 2021
Est. primary completion date March 15, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Understand and read Norwegian - No cognitive barriers. The woman must be able to give informed consent - = 37 gestational week, vertex presentation, single pregnancy - Normal ultrasound including fetal movements, amniotic fluid, estimated fetal weight +/- 15% (= 10 percentile and = 90) and normal doppler peak systolic index in the umbilical cord artery and the cerebri media artery - Normal cardiotocography - Body Mass Index 18-35 - No signs of infection or health problems - Distance to hospital 45-60 minutes Exclusion Criteria: - Premature rupture of membranes - Previous cesarean section or operation on uterus - Fetal anomaly or chromosome/genetic disorder - Pregnancy complications such as preeclampsia and diabetes (insulin dependent) or other conditions were changes in fetal heart rate during labor is suspected - Not eligible for misoprostol as induction agent due a favorable cervix (Bishop score) and/or previous obstetric history

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Inpatient setting
These women stay at the hospital.
Outpatient setting
These women can leave the hospital.

Locations

Country Name City State
Norway Sorlandet Hospital Trust Kristiansand

Sponsors (1)

Lead Sponsor Collaborator
Sorlandet Hospital HF

Country where clinical trial is conducted

Norway, 

References & Publications (5)

Alfirevic Z, Aflaifel N, Weeks A. Oral misoprostol for induction of labour. Cochrane Database Syst Rev. 2014 Jun 13;(6):CD001338. doi: 10.1002/14651858.CD001338.pub3. Review. — View Citation

Diederen M, Gommers J, Wilkinson C, Turnbull D, Mol B. Safety of the balloon catheter for cervical ripening in outpatient care: complications during the period from insertion to expulsion of a balloon catheter in the process of labour induction: a systematic review. BJOG. 2018 Aug;125(9):1086-1095. doi: 10.1111/1471-0528.15047. Epub 2018 Jan 10. — View Citation

Vogel JP, Osoti AO, Kelly AJ, Livio S, Norman JE, Alfirevic Z. Pharmacological and mechanical interventions for labour induction in outpatient settings. Cochrane Database Syst Rev. 2017 Sep 13;9:CD007701. doi: 10.1002/14651858.CD007701.pub3. Review. — View Citation

WHO Recommendations for Induction of Labour. Geneva: World Health Organization; 2011. — View Citation

Wilkinson C, Bryce R, Adelson P, Turnbull D. A randomised controlled trial of outpatient compared with inpatient cervical ripening with prostaglandin E2 (OPRA study). BJOG. 2015 Jan;122(1):94-104. doi: 10.1111/1471-0528.12846. Epub 2014 May 14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The feasibility of a randomised controlled trial of outpatient labor induction The number of eligible women who is willing to enrol in participating 6 months
Secondary Reported labor experience among the women participating The women will fill out a survey before and after birth (including childbirth expectations, experience and satisfaction) From included in the study until postpartum discharge (1-2 weeks)
Secondary Maternal length of hospital stay Length of hospital stay form start of induction to postpartum discharge From included in the study until postpartum discharge (1-2 weeks)
Secondary Use of analgesia Use of epidural and fentanyl analgesia during labor From start of the partogram until birth (hours)
See also
  Status Clinical Trial Phase
Terminated NCT00141895 - A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Termination for Intrauterine Fetal Death Phase 3
Completed NCT03039036 - Early Amniotomy Versus Delayed Amniotomy Following Foley Catheter Ripening in Nulliparous Labor Induction N/A
Completed NCT05827731 - Cervical Double Balloon Combined With Oxytocin N/A
Recruiting NCT04035382 - BMI-Associated Labor Induction: A Prospective Trial N/A
Withdrawn NCT00771511 - Cervical Capsaicin for Labor Induction and Pain Relief Phase 4
Recruiting NCT04075630 - Observatory on Artificial Labour-induction Methods and Measuring Immediate Postpartum Maternal Satisfaction
Active, not recruiting NCT04573517 - Early Amniotomy Following Transcervical Foley Balloon in the Induction of Labor N/A
Withdrawn NCT05257187 - Foley Catheter Induction N/A
Recruiting NCT03016442 - Dinoprostone Vaginal Insert Versus Double Balloon Catheter for Preinduction Cervical Ripening Phase 2
Not yet recruiting NCT00984347 - Breast Stimulation Versus Pitocin for Induction of Labor N/A
Completed NCT03504670 - Preterm Induction of Labor Timing of Amniotomy: A Randomized Controlled Trial N/A
Completed NCT00886860 - The Comparison of Efficacy for Cervical Ripening in Labor Induction Between Titrated and Conventional Oral Misoprostol Phase 4
Completed NCT00504465 - Combined Agent Randomized Trial of Induction of Labor N/A
Completed NCT01402050 - Foley Catheter Versus Cervidil for Induction of Labor at Term N/A
Completed NCT01170819 - Double Balloon Catheter Versus Dinoprostone Vaginal Insert for Cervical Ripening. Phase 4
Completed NCT00529295 - Titrated Oral Compared With Vaginal Misoprostol for Labor Induction at Term Phase 3
Completed NCT00346840 - Safety and Efficacy Study of Misoprostol Vaginal Insert for Induction of Labour Phase 2
Completed NCT00442663 - Trial of Foley Catheter With and Without Extra-Amniotic Saline Infusion for Labor Induction N/A
Withdrawn NCT03218735 - Early Term Delivery Versus Expectant Management of the Large for Gestational Age Fetus N/A
Completed NCT02639429 - Cervical Ripening for Obese Women: A Randomized, Comparative Effectiveness Trial Phase 4